克雷森特生物制药
CBIO
11.84
-0.64
-5.13%
克雷森特生物制药
US · CBIO
#3749 按市值排名
11.84
-0.64
-5.13%
实时 - 追踪5344个代码 - 心跳于568秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量增加了3家。
- 机构持股总比例下降了20.8个百分点。
机构持股
- 机构持股比例
- 83.68% -20.75pp
- 机构数量
- 104 +3
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Hedge Fund36.99%
Mutual Fund24.63%
Private Company11.72%
VC/PE Fund9.39%
Individual/Insider3.86%
Sovereign Wealth Fund0.61%
Public Company0.20%
Insurance Company0.11%
Other12.46%
主要股东 截至 2025-04-15
Paragon Therapeutics, Inc.
11.68% · 5.00M 股
FMR
9.66% · 4.13M 股
Fairmount Funds Management LLC
8.41% · 3.60M 股
BVF Partners L.P.
6.42% · 2.75M 股
VR Management, LLC
4.98% · 2.13M 股
Logos Global Management, L.P.
4.44% · 1.90M 股
Forbion Capital Partners B.V.
3.92% · 1.68M 股
Balyasny Asset Management L.P.
3.89% · 1.66M 股
Vestal Point Capital, LP
3.81% · 1.63M 股
Jiaqiang Li
3.33% · 1.43M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪25份申报 · 20次买入 · 4次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Edwin Rock | Senior VP & Chief Medical Officer | 0.02% |
| Brian Hahn | Senior Vice President | 0.00% |
| Harout Semerjian | Chief Executive Officer | 0.00% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2024-08-07 | Artal Group S.A. | -- | Open Market Disposition | -322,361 | $0.18–0.19 |
| 2024-08-05 | Artal Group S.A. | -- | Open Market Disposition | -220,255 | $0.18–0.19 |
| 2024-08-01 | Artal Group S.A. | -- | Open Market Disposition | -349,764 | $0.20–0.22 |
| 2024-07-29 | Artal Group S.A. | -- | Open Market Disposition | -1,379,119 | $0.22–0.24 |
| 2024-07-24 | Artal Group S.A. | -- | Initial Statement of Beneficial | 0 | -- |
| 2024-06-20 | Edwin Rock | Senior VP & Chief Medical Officer | Open Market Acquisition | +305,000 | $0.25–0.27 |
| 2024-06-17 | Brian Hahn | Senior Vice President | Open Market Acquisition | +17,500 | $0.25 |
| 2024-04-30 | Daniel Junius | Independent Director | Other Derivative Acquisition | +40,000 | $1.62 |
| 2024-04-30 | Mark Goldberg | -- | Other Derivative Acquisition | +40,000 | $1.62 |
| 2024-04-30 | Timothy Pearson | Independent Chairperson | Other Derivative Acquisition | +40,000 | $1.62 |
| 2024-04-30 | Scott Koenig | Independent Director | Other Derivative Acquisition | +40,000 | $1.62 |
| 2024-04-30 | Rachel King | Co-Founder | Other Derivative Acquisition | +40,000 | $1.62 |
| 2024-04-30 | Scott Jackson | Independent Director | Other Derivative Acquisition | +40,000 | $1.62 |
| 2024-04-30 | Patricia Susan Andrews | Independent Director | Other Derivative Acquisition | +40,000 | $1.62 |
| 2024-03-28 | Daniel Junius | Independent Director | Other Acquisition | +5,209 | $3.00 |
| 2024-03-28 | Mark Goldberg | -- | Other Acquisition | +4,584 | $3.00 |
| 2024-03-28 | Rachel King | Co-Founder | Other Acquisition | +3,334 | $3.00 |
| 2024-01-11 | Brian Hahn | Senior Vice President | Other Derivative Acquisition | +250,000 | $3.11 |
| 2024-01-11 | Harout Semerjian | Chief Executive Officer | Other Derivative Acquisition | +695,000 | $3.11 |
| 2024-01-11 | Edwin Rock | Senior VP & Chief Medical Officer | Other Derivative Acquisition | +250,000 | $3.11 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:12 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
克雷森特生物制药 讨论区 0 条评论